Equities

Adcock Ingram Holdings Ltd

Adcock Ingram Holdings Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (ZAX)6,780.00
  • Today's Change49.00 / 0.73%
  • Shares traded7.01k
  • 1 Year change+24.43%
  • Beta0.4238
Data delayed at least 15 minutes, as of Nov 21 2024 15:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Adcock Ingram Holdings Limited is a South Africa-based healthcare company. The Company’s segments include Consumer, Over the Counter (OTC), Prescription, Hospital, and Other. The Consumer segment is engaged mainly in the fast-moving consumer goods (FMCG) space. Its OTC segment focuses on brands sold predominantly in pharmacies. Its Prescription segment markets products prescribed by medical practitioners, and specialized instruments and surgical products. Its Hospital segment supplies hospital and critical care products, including intravenous solutions, blood collection products and renal dialysis systems. Its Other segment include shared services and other support services, including regulatory services in India, as well as the investment in the joint venture and cash and bank overdraft balances which are managed on a central basis in Southern Africa.

  • Revenue in ZAR (TTM)9.64bn
  • Net income in ZAR814.01m
  • Incorporated2007
  • Employees2.44k
  • Location
    Adcock Ingram Holdings Ltd1 New Road, (c/o New Road & 7th Street)MIDRAND 1682South AfricaZAF
  • Phone+27 116350000
  • Fax+27 865530000
  • Websitehttps://www.adcock.co.za/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SeQuent Scientific Ltd3.11bn35.40m10.44bn1.20k298.297.1652.483.350.65370.653757.2527.230.94642.284.4612,129,000.001.791.092.941.7645.8641.971.891.180.95641.260.397435.06-3.605.6870.40--6.96--
Shandong Boan Biotechnology Co Ltd1.80bn154.74m10.73bn777.0065.902.9332.685.950.13050.13051.522.940.30691.102.60952,026.102.63--3.43--74.10--8.59--1.034.010.3369--19.80--64.02------
Chengdu Olymvax Biopharmaceuticals Inc1.33bn-21.77m10.78bn471.00--4.73--8.13-0.0219-0.02191.312.240.33010.36851.041,126,255.00-0.91433.17-1.284.6894.1993.00-2.777.441.67-0.53920.29159.82-9.3845.40-33.94--56.47--
Phathom Pharmaceuticals Inc476.11m-6.15bn10.82bn452.00------22.72-5.69-5.690.4398-2.740.08422.68--58,119.47-108.79-83.26-126.95-93.7783.54---1,292.14-135,982.005.68-5.601.56-------1.96------
Adcock Ingram Holdings Limited9.64bn814.01m10.86bn2.44k12.801.64--1.135.265.2662.3640.941.162.574.503,958,591.009.8010.2413.9714.4433.3830.348.449.050.9267--0.049341.415.606.38-9.393.37-9.936.58
Tibet Weixinkang Pharmaceutical Co Ltd3.14bn617.90m10.96bn701.0017.742.96--3.490.56770.56772.893.410.677816.415.561,791,483.0013.338.2017.0111.1353.4550.2019.6711.533.27--0.007559.11-5.4312.1320.9423.85-5.6138.96
Lionco Pharmaceutical Group Co Ltd693.32m-254.63m10.99bn475.00--5.13--15.85-0.144-0.1440.38281.190.18432.484.41583,571.30-6.770.7396-7.850.956241.7780.88-36.732.084.94-4.740.2409521.93-31.95-34.7922.65---33.18--
Zhejiang Shouxiangu Pharmaceuticl Co Ltd1.79bn584.75m11.04bn1.14k18.671.98--6.191.191.193.6311.260.23670.71947.25624,455.807.7510.049.0911.6380.0183.6632.7528.293.48--0.209847.86-5.398.93-8.3918.7812.2317.13
Kyorin Pharmaceutical Co Ltd13.96bn561.54m11.05bn2.04k17.500.648210.260.791683.8383.832,084.192,263.350.67451.213.1858,635,650.002.713.053.363.7942.8747.114.024.761.74--0.159367.745.531.0212.68-4.987.41-7.06
Eyepoint Pharmaceuticals Inc828.48m-1.88bn11.05bn121.00--2.19--13.34-2.01-2.010.90184.090.19831.05106.19377,793.40-44.94-40.44-59.48-47.7991.4883.45-226.57-186.235.45--0.00--11.14--30.77------
Data as of Nov 21 2024. Currency figures normalised to Adcock Ingram Holdings Ltd's reporting currency: South African Rand ZAR

Institutional shareholders

13.07%Per cent of shares held by top holders
HolderShares% Held
Public Investment Corporation (SOC) Ltd.as of 30 Jun 202315.34m9.04%
Old Mutual Customised Solutions (Pty) Ltd.as of 30 Jun 20241.22m0.72%
Dimensional Fund Advisors LPas of 07 Nov 20241.17m0.69%
BlackRock Fund Advisorsas of 07 Nov 2024909.72k0.54%
Abax Investments (Pty) Ltd.as of 30 Sep 2024840.00k0.50%
ClucasGray Investment Management (Pty) Ltd.as of 29 Mar 2024820.08k0.48%
Merchant West Investments (Pty) Ltd.as of 30 Aug 2024603.38k0.36%
Centaur Asset Management Pty Ltd.as of 30 Sep 2024567.79k0.34%
Camissa Asset Management Pty Ltd.as of 31 Mar 2024376.04k0.22%
Bateleur Capital (Pty) Ltd.as of 31 Mar 2024335.88k0.20%
More ▼
Data from 29 Mar 2024 - 11 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.